| 词条 | Copper aspirinate |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 418579364 | ImageFile1 = Copper_aspirinate.jpg | ImageSize1 = | ImageFile2 = Cu2(asp)4.png | ImageSize2 = | ImageFile3 = Copper(II)-aspirinate-3D-balls.png | IUPACName = dicopper 2-acetyloxybenzoate | OtherNames = tetrakis-μ-acetylsalicylato-dicopper(II), copper(II) aspirinate, cupric acetylsalicylate, cupric aspirinate, cupric aspirin complex |Section1={{Chembox Identifiers | Abbreviations = | CASNo_Ref = {{cascite|correct|??}} | CASNo = 23642-01-5 | EINECS = | PubChem = 92244 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 83280 | SMILES = CC(=O)Oc1ccccc1C(=O)[O-].CC(=O)Oc1ccccc1C(=O)[O-].CC(=O)Oc1ccccc1C(=O)[O-].CC(=O)Oc1ccccc1C(=O)[O-].[Cu+2].[Cu+2] | InChI = 1/4C9H8O4.2Cu/c4*1-6(10)13-8-5-3-2-4-7(8)9(11)12;;/h4*2-5H,1H3,(H,11,12);;/q;;;;2*+2/p-4 | InChIKey = BXBJCCCIFADZBU-XBHQNQODAY | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/4C9H8O4.2Cu/c4*1-6(10)13-8-5-3-2-4-7(8)9(11)12;;/h4*2-5H,1H3,(H,11,12);;/q;;;;2*+2/p-4 | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = BXBJCCCIFADZBU-UHFFFAOYSA-J | RTECS = | MeSHName = | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = | SMILES1 = CC(=O)Oc0ccccc0[c-](O[Cu+2]123)O[Cu+2](O[c-](O1)c0ccccc0OC(=O)C)(O[c-](O2)c0ccccc0OC(=O)C)O[c-](O3)c0ccccc0OC(=O)C }} |Section2={{Chembox Properties | Formula = C36H28Cu2O16 | MolarMass = 843.69g/mol | Appearance = Bright blue crystalline solid. | Density = | MeltingPtC = 248 to 255 | MeltingPt_notes = (decomposes) | BoilingPt = | BoilingPt_notes = | Solubility = | SolubleOther = | Solvent = | pKa = | pKb = }} |Section3={{Chembox Structure | CrystalStruct = | Coordination = | MolShape = }} |Section4={{Chembox Thermochemistry | DeltaHf = | DeltaHc = | Entropy = | HeatCapacity = }} |Section5={{Chembox Pharmacology | AdminRoutes = | Bioavail = | Metabolism = | HalfLife = 8.67 h (Human)[Ref#2] | ProteinBound = | Excretion = | Legal_status = | Legal_US = | Legal_UK = | Legal_AU = | Legal_CA = | Pregnancy_category = | Pregnancy_AU = | Pregnancy_US = }} |Section6={{Chembox Explosive | ShockSens = | FrictionSens = | DetonationV = | REFactor = }} |Section7={{Chembox Hazards | EUClass = | MainHazards = | NFPA-H = | NFPA-F = | NFPA-R = | NFPA-S = | RPhrases = | SPhrases = | RSPhrases = | FlashPt = | AutoignitionPt = | ExploLimits = | PEL = TWA 1 mg/m3 (as Cu)[1] | REL = TWA 1 mg/m3 (as Cu)[1] | IDLH = TWA 100 mg/m3 (as Cu)[1] }} |Section8={{Chembox Related | OtherAnions = | OtherCations = Zinc aspirinate, Aluminium aspirinate | OtherFunction = | OtherFunction_label = | OtherCompounds = Aspirin}} }} Copper(II) aspirinate is an aspirin chelate of copper(II) cations (Cu2+). It is used to treat rheumatoid arthritis. PreparationCopper aspirinate can be prepared by several methods. In one route of preparation, an excess of acetylsalicylic acid is dissolved in aqueous sodium carbonate. Sodium hydroxide is not suitable for this purpose, because it will hydrolyse acetylsalicylic acid (ASA) into salicylic acid and sodium acetate. 2 HC9H7O4 + Na2CO3 → 2 NaC9H7O4 + CO2↑ + H2O The resulting solution is then filtered to remove any undissolved acetylsalicylic acid and is mixed with a solution containing Cu2+ cations (copper(II) sulfate is suitable), precipitating bright blue crystals of copper aspirinate immediately. The crystals can then be filtered from solution, washed, and dried. An excess of acetylsalicylic acid is used in the first step, because it eliminates the possibility of unreacted carbonate anions precipitating the copper in this step. 4 NaC9H7O4 + 2 CuSO4 → C36H28Cu2O16↓ + 2 Na2SO4 Medicinal useCopper aspirinate has been proven effective as a treatment for rheumatoid arthritis.[2] A pharmacokinetic study in healthy human volunteers supports its enhanced efficacy as compared with aspirin.[3] The studies on animal models suggest that copper aspirinate is very promising in treating against thrombotic diseases and it has all the prospects of success in becoming an antithrombotic drug that prevents and treats thrombotic diseases in humans.[4] Other usesThe use of copper aspirinate as a pigment in PVC and Polystyrene has also been investigated.[5] External links
Footnotes1. ^1 2 {{PGCH|0150}} {{salicylates}}{{DEFAULTSORT:Copper Aspirinate}}2. ^{{cite web | last = | first = | title = Rheumatoid Arthritis (RA) | publisher = Copper Development Association | date = June 2000 | url = http://www.copper.org/innovations/2000/06/medicine-chest.html }} 3. ^ MS Iqbal, M Sher, H Pervez & M Saeed (2008). "Pharmacokinetic Study of Copper (II) Acetylsalicylate" Biol. Trace Elem. Res. 124:283–288. doi:10.1007/s12011-008-8146-3 4. ^{{cite journal | title = Potential Application of Copper Aspirinate in Preventing and Treating Thromboembolic Diseases |journal =Met Based Drugs. | publisher = Hindawi Publishing Corporation | year = 1998 |volume = 5 |issue = 3 |pages = 123–126 |doi = 10.1155/MBD.1998.123 |url = http://www.copper.org/innovations/2000/06/medicine-chest.html |author = Weiping Liu,corresponding author1 Huizhou Xiong, Yikun Yang Ling Li, Zhiqiang Shen, and Zhihe Chen | pmid = 18475833 | pmc = 2365110 }} 5. ^{{cite journal | last = Allan | first = J R |author2=A Renton |author3=W E Smith |author4=D L Gerrard |author5=J Birnie | title = A Study of the Performance of Bis(acetylsalicylate) Copper(II) and the Cobalt(II), Nickel(II) and Copper(II) Complexes of Pyridine-3,4-dicarboxylic Acid as Colouring Materials for Poly(vinyl chloride) and Polystyrene | journal = Eur. Polym. J. | volume = 27 | issue = 7 | pages = 669–672 | publisher = | year = 1991 | url = | accessdate = | doi = 10.1016/0014-3057(91)90155-H }} 2 : Copper(Ⅱ) compounds|Benzoates |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。